Cyclic lipopeptide antibiotic derived from a fermentation product of Streptomyces roseosporus; disrupts plasma membrane function in gram-positive bacteria. Prepn: B. J. Abbott et al., US 4537717 (1985 to Eli Lilly); M. Debono et al., J. Antibiot. 41, 1093 (1988). Mechanism of action study: N. E. Allen et al., Antimicrob. Agents Chemother. 31, 1093 (1987); and structure determn: D. Jung et al., Chem. Biol. 11, 949 (2004). Comparative in vitro antibacterial spectrum: I. A. Critchley et al., J. Antimicrob. Chemother. 51, 639 (2003). Clinical pharmacokinetics: J. R. Woodworth et al., Antimicrob. Agents Chemother. 36, 318 (1992). Clinical trial in skin infections: R. D. Arbeit et al., Clin. Infect. Dis. 38, 1673 (2004). Review of pharmacology and clinical evaluations: F. P. Tully et al., Expert Opin. Invest. Drugs 8, 1223-1238 (1999); L. P. Kotra Curr. Opin. Anti-Infect. Invest. Drugs 2, 185-205 (2000).
Antibacterial.
Antibacterial (Antibiotics); Polypeptides